Travere Therapeutics, Inc. (TVTX)

NASDAQ: TVTX · Real-Time Price · USD

28.18

-0.09 (-0.32%)

At close: Mar 4, 2026, 4:00 PM EST

28.05

-0.13 (-0.46%)

After-hours: Mar 4, 2026, 6:50 PM EST

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Development and Commercialization of Innovative Therapies	490.73M	233.18M	145.24M	109.46M	131.84M
Development and Commercialization of Innovative Therapies Growth	110.45%	60.55%	32.69%	-16.97%	-33.52%
Total	490.73M	233.18M	145.24M	109.46M	131.84M
Total Growth	110.45%	60.55%	32.69%	-16.97%	-33.52%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
United States	490.73M	233.18M	145.24M	109.46M	131.84M
United States Growth	110.45%	60.55%	32.69%	-16.97%	-33.52%
Total	490.73M	233.18M	145.24M	109.46M	131.84M
Total Growth	110.45%	60.55%	32.69%	-16.97%	-33.52%

Source: S&P Global Market Intelligence.